Mankind Pharma (NSE: MANKIND, BSE: 543904) is a New Delhi, Delhi-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹91,379 Cr, it ranks #117 by market cap among the 6,189 Indian listed companies on FinBizNet, and #6 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,212.60 (as of 26 Oct 2026), the share price is 16.3% below its 52-week high of ₹2,642.00 and 15.9% above its 52-week low of ₹1,909.70. The share price is down 9.9% over one year and down 11.8% over three months.
| Current Price | ₹2,212.60 |
|---|---|
| Market Cap | ₹91,379 Cr |
| NSE Symbol | MANKIND |
| BSE Code | 543904 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 47.8 |
| Return on Equity | 12.45% |
| Return on Assets | 6.31% |
| 52-Week Range | ₹1,909.70 – ₹2,642.00 |
| 1-Year Price Change | -9.9% |
| 3-Month Price Change | -11.8% |
| Beta (1Y) | 0.47 |
| Dividend Yield | 0.09% |
| Headquarters | New Delhi, Delhi |
| Website | www.mankindpharma.com |
| Revenue | ₹4,031 Cr |
|---|---|
| Net Profit | ₹570 Cr |
| Net Margin | 14.1% |
| EPS (Basic) | ₹13.76 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboo
1. Pharmaceuticals-This segment develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. 2. 0-0 3. 0-0 4. 0-0
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Glenmark Pharmaceuticals Limited | ₹61,142 Cr | 44.9 | 14.07% | ₹4,018 Cr | +16.2% |
Listed by market capitalisation. Ratios are shown for context only.
Mankind Pharma is trading at ₹2,212.60, with a market capitalisation of ₹91,379 Cr.
Mankind Pharma operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Mankind Pharma has a P/E of 47.8 and a return on equity of 12.45%.
Mankind Pharma is listed on the NSE under the symbol MANKIND and on the BSE under the scrip code 543904.
Mankind Pharma's share price is down 9.9% over one year and down 11.8% over three months. Its 52-week range is ₹1,909.70 to ₹2,642.00.
In Q1 FY27, Mankind Pharma reported revenue of ₹4,031 Cr and net profit of ₹570 Cr, with basic EPS of ₹13.76 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.